Score Overview
Explore the 2021 public Archive ranking →
Where China SXT Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SXTC does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 0.05 | — |
1 Year2025-10-22 | $ 15.66K | -100.00% |
5 Years2021-10-22 | $ 1000K | -100.00% |
All Time2019-01-04 | $ 1000K | -100.00% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | All Time2019-01-04 |
|---|---|---|---|---|
| Price | $ 0.05 | $ 15.66K | $ 1000K | $ 1000K |
| Return | — | -100.00% | -100.00% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 2M | -$ 6M | $ 28M |
| 2026 | $ 1M | -$ 6M | $ 28M |
| 2025 | $ 1M | -$ 3M | $ 18M |
| 2024 | $ 1M | -$ 3M | $ 12M |
| 2023 | $ 1M | -$ 5M | $ 17M |
| 2022 | $ 2M | -$ 5M | $ 15M |
| 2021 | $ 4M | -$ 2M | $ 13M |
| 2020 | $ 5M | -$ 10M | $ 7M |
| IPO2019 | $ 7M | $ 1M | $ 9M |
China SXT Pharmaceuticals Inc fundamental performance
Between 2021 and 2026, revenue declined from $ 4M to $ 1M and net income went from -$ 2M to -$ 6M. Revenue increased in 1 of those 5 years; net income in 2.
China SXT Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.
Membership
Explore SXTC with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
